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Correction: Routine HIV Testing in Botswana: A Population-Based Study 
on Attitudes, Practices, and Human Rights Concerns
Sheri D. Weiser, Michele Heisler, Karen Leiter, Fiona Percy-de Korte, Sheila Tlou, Sonya DeMonner, Nthabiseng Phaladze, 
David R. Bangsberg, Vincent Iacopino
DOI: 10.1371/journal.pmed.0030261
In PLoS Medicine, volume 3, issue 7:
Table 3 should have listed Age (years) as Mean: 28.5, SD: 8.3 (not Mean: 8.3, SD: 9.6). 
Minnehy Mukoma should have been included in the Acknowledgments for research design and implementation. 
This correction note may be found online at DOI: 10.1371/journal.pmed.0030395.
Published October 31, 2006.
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Correction: Frequency of Adverse Events after Vaccination with Different Vaccinia 
Strains
Mirjam Kretzschmar, Jacco Wallinga, Peter Teunis, Shuqin Xing, Rafael Mikolajczyk
DOI: 10.1371/journal.pmed.0030272
In PLoS Medicine, volume 3, issue 8: 
Under the section heading “Expected Death Toll during a Present-Day Mass Vaccination Campaign,” the numbers of 
expected deaths that were computed for a mass vaccination campaign were displayed as per million; they should be 
absolute numbers.
The corrected text should be: “Under those assumptions, in the Netherlands mass vaccination with NYCBH would lead to 9.8 
deaths (95% CI [0, 30]), mass vaccination with Lister to 55.1 deaths (95% CI [7, 182]), and mass vaccination with Bern would 
lead to 303.5 deaths (95% CI [19, 1093]). In Germany mass vaccination with NYCBH would lead to 46.2 deaths (95% CI [6, 
142]), mass vaccination with Lister would lead to 268.5 deaths (95% CI [39, 875]), and mass vaccination with Bern would lead 
to 1,381 deaths (95% CI [94, 4909]).”
This correction note may be found online at DOI: 10.1371/journal.pmed.0030429.
Published October 31, 2006
Citation: Correction: Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med 3(10): 
e429. DOI: 10.1371/journal.pmed.0030429
Correction: Regulating the Market in Human Research Participants
Trudo Lemmens, Paul B. Miller
DOI: 10.1371/journal.pmed.0030330
In PLoS Medicine, volume 3, issue 8: 
Reference 13 was mistakenly not cited in the main article. It should have been added as a reference to the sentence: “Claims 
associated with costs of drug development merit careful scrutiny since they are often used as a rhetorical tool to argue for 
faster approval times or to justify the high price of pharmaceuticals [13].”
This correction note may be found online at DOI: 10.1371/journal.pmed.0030447.
Published October 31, 2006.
Citation: Correction: Regulating the market in human research participants. PLoS Med 3(10): e447. DOI: 10.1371/
journal.pmed.0030447